Research and development to support the investigation of novel antimalarial drug targets through affinity-based pulldowns.
Active Definitive Contract Awarded Last action
- Contract number
- HT942525CE040
- Awardee
-
Portland State University UEI H4CAHK2RD945
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $46,491
Award facts
- Contract value 77% obligated
-
- $46,491.01 Current, with exercised options
- $60,459.98 Potential, with all options
- Completion date 52% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Not Competed · 1 offer Only One Source
- Pricing
- Cost No Fee
- Place of performance
- Portland, OR 97207, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Health Agency has awarded a $60,459.98 cost-no-fee definitive contract to Portland State University for research and development supporting the investigation of novel antimalarial drug targets through affinity-based pulldowns. The contract, awarded on September 30, 2025, is scheduled for completion by September 29, 2027, with performance occurring at PSU's Portland, Oregon campus. No set-aside designation was applied to this award, reflecting competitive procurement practices. This research initiative aligns with the Defense Health Agency's mission to advance medical countermeasures and therapeutic solutions relevant to military health and readiness, particularly for addressing malaria as a potential threat to deployed personnel and global health operations.
Portland State University, a prominent public research institution with extensive federal contracting experience, brings established capabilities in scientific research and interdisciplinary investigations to this effort. The university has demonstrated success in securing competitive federal awards across multiple agencies and scientific domains, including the National Institutes of Health and National Science Foundation. The affinity-based pulldown methodology employed in this antimalarial research represents a biochemical approach to identify and validate drug targets, contributing to the broader development pipeline for novel antimalarial therapeutics that could benefit both military and civilian populations.
Quick answers
Who was awarded contract HT942525CE040?
HT942525CE040 was awarded to Portland State University by Defense Health Agency (Department of Defense) on September 30, 2025.
How much is contract HT942525CE040 worth?
The government has obligated $46,491 on HT942525CE040. Its potential value, with all options, is $60,460.
Was contract HT942525CE040 competed?
The extent of competition for HT942525CE040 was not competed. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award